Comparison of prevalent management options to treat acute central serous chorioretinopathy

被引:0
|
作者
Pradhan, Atish K. [1 ]
Behera, Umesh C. [1 ,2 ]
机构
[1] LV Prasad Eye Inst, Retina Vitreous Serv, Anant Bajaj Retina Inst, Mithu Tulsi Chanrai Campus, Bhubaneswar, Odisha, India
[2] LV Prasad Eye Inst, Bhubaneswar 751024, Odisha, India
关键词
Acute; central serous chorioretinopathy; lasers; natural history; placebo treatment; RISK-FACTORS; FINASTERIDE; DETACHMENT; EPLERENONE; UPDATE;
D O I
10.4103/IJO.IJO_677_23
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To study the acute central serous chorioretinopathy (CSC) management strategies practiced at a tertiary eye care center in eastern India. Methods: In a retrospective chart review study, the clinical outcomes of three different management approaches to treating acute CSC were analyzed. Individuals with follow-ups of fewer than 6 months were excluded. Logistic regression analysis was performed to identify the prognostic markers of CSC resolution. Results: In the 10-year study period (January 2013-July 2022), 206 eyes were included. Placebo treatment was the preferred practice (48.5%; n = 100 eyes). Watchful observation without placebo was the management strategy in 30.6% (n = 63) of the eyes, and 20.9% (n = 43) of eyes received focal lasers. Risk factor modification was attempted in all. There was no significant difference in the resolution rate (P = 0.819), time to resolution (P = 0.331), and disease recurrence (P = 0.067) among the groups. Univariate logistic regression analysis did not favor any of the treatment strategies predicting resolution and recurrence. Conclusion: Alternative treatment modes did not score over the natural history of acute CSC regarding disease resolution, vision gain, and disease recurrence. The study reaffirms observation as the standard of care for acute CSC.
引用
收藏
页码:3563 / 3568
页数:6
相关论文
共 50 条
  • [1] CENTRAL SEROUS CHORIORETINOPATHY - TO TREAT OR NOT TO TREAT
    DELAEY, JJ
    DOCUMENTA OPHTHALMOLOGICA, 1986, 61 (3-4) : 367 - 372
  • [2] Central Serous Chorioretinopathy: Multimodal Imaging and Management Options
    Iyer, Prashanth G.
    Schwartz, Stephen G.
    Russell, Jonathan F.
    Flynn, Harry W.
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2020, 2020
  • [3] Commentary: Acute central serous chorioretinopathy - Treat early, observe longer
    Kumar, Nilesh
    Parachuri, Nikulaa
    Sharma, Ashish
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (09) : 2347 - +
  • [4] Eplerenone fails to treat central serous chorioretinopathy
    Sandhu, Harpal
    Vavvas, Demetrios G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [5] Eplerenone use to treat Central Serous Chorioretinopathy
    Moreno, Javier
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [6] Therapy options for chronic central serous chorioretinopathy
    Maier, M.
    Valet, V.
    Feucht, N.
    Lohmann, C. P.
    OPHTHALMOLOGE, 2011, 108 (11): : 1027 - 1031
  • [7] Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy
    Goldhagen B.E.
    Goldhardt R.
    Current Ophthalmology Reports, 2017, 5 (2) : 141 - 148
  • [8] Endpoint management in central serous chorioretinopathy
    Shekoh, Noor-Ul-Ain
    Shekoh, Quratulain
    Gonzalez, Victor
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [9] Central Serous Chorioretinopathy: Pathogenesis and Management
    Semeraro, Francesco
    Morescalchi, Francesco
    Russo, Andrea
    Gambicorti, Elena
    Pilotto, Andrea
    Parmeggiani, Francesco
    Bartollino, Silvia
    Costagliola, Ciro
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 2341 - 2352